CD73 inhibitors
The present invention provides 5-[5]-[2-cycloalkyl]-6-pyridazin-3-yl]-1H-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer.
1. A compound of the formula:
wherein n is 0-3;
R 1 is —H, —F, -gem-difluoro, -gem-dimethyl,
—C 1-4 alkyl, —CHF 2 , —CF 2 CH 3 or —CH 2 CH 2 F; and
R 2 is selected from —H, —CH 3 , —F, —Cl, —CN, or —OCH 3 ;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , which is:
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2 , which is:
or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 2 , which is:
or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 4 , which is:
or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 1 ,
wherein n is 0, R 1 is —C 1-4 alkyl, and R 2 is —CH 3 ,
or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 6 , wherein R 1 is isopropyl, or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 1 , which is
or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 2 , which is:
or a pharmaceutically acceptable salt thereof.
10. The compound according to claim 9 , which is 5-[5-[(1S,2R)-2-isopropylcyclopropyl]-6-methyl-pyridazin-3-yl]-1H-pyrimidine-2,4-dione, or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 2 , which is:
or a pharmaceutically acceptable salt thereof.
12. The compound according to claim 11 , which is 5-[5-[(1S,2S)-2-ethylcyclopropyl]-6-methyl-pyridazin-3-yl]-1H-pyrimidine-2,4-dione, or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a compound of the formula:
wherein n is 0-3;
R 1 is —H, —F, -gem-difluoro, -gem-dimethyl, —C 1-4 alkyl, —CHF 2 , —CF 2 CH 3 or —CH 2 CH 2 F; and
R 2 is selected from —H, —CH 3 , —F, —Cl, —CN, or —OCH 3 ;
or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
14. A method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound of the formula:
wherein n is 0-3;
R 1 is —H, —F, -gem-difluoro, -gem-dimethyl, —C 1-4 alkyl, —CHF 2 , —CF 2 CH 3 or —CH 2 CH 2 F; and
R 2 is selected from —H, —CH 3 , —F, —Cl, —CN, or —OCH 3 ;
or a pharmaceutically acceptable salt thereof,
wherein the cancer is bladder cancer, breast cancer, cholangiocarcinoma, colorectal cancer, colon cancer, gastric cancer, gallbladder cancer, glioblastoma, head and neck cancer, liver cancer, lung cancer, lymphoma, medulloblastoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer or renal cancer.
15. The method of claim 14 , wherein the patient is one in whom serum CD73 activity has been determined.
16. The method of claim 14 , wherein the patient is one in whom tissue CD73 expression has been determined.
17. A method, comprising determining CD73 activity in the serum of a patient to whom a compound of the formula:
wherein n is 0-3;
R 1 is —H, —F, -gem-difluoro, -gem-dimethyl, —C 1-4 alkyl, —CHF 2 , —CF 2 CH 3 or —CH 2 CH 2 F; and
R 2 is selected from —H, —CH 3 , —F, —Cl, —CN, or —OCH 3 ;
or a pharmaceutically acceptable salt thereof, has been administered.
18. A method, comprising determining CD73 expression in tissue from a patient to whom a compound of the formula:
wherein n is 0-3;
R 1 is —H, —F, -gem-difluoro, -gem-dimethyl, —C 1-4 alkyl, —CHF 2 , —CF 2 CH 3 or —CH 2 CH 2 F; and
R 2 is selected from —H, —CH 3 , —F, —Cl, —CN, or —OCH 3 ;
or a pharmaceutically acceptable salt thereof, has been administered.
19. The pharmaceutical composition according to claim 13 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
20. The pharmaceutical composition according to claim 19 , wherein the compound is 5-[5-[(1S,2R)-2-isopropylcyclopropyl]-6-methyl-pyridazin-3-yl]-1H-pyrimidine-2,4-dione, or a pharmaceutically acceptable salt thereof.
21. The method according to claim 14 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
22. The method according to claim 21 , wherein the compound is 5-[5-[(1S,2R)-2-isopropylcyclopropyl]-6-methyl-pyridazin-3-yl]-1H-pyrimidine-2,4-dione, or a pharmaceutically acceptable salt thereof.